Jade Biosciences (JBIO) Net Cash Flow Growth (1y) (2021 - 2026)
Jade Biosciences (JBIO) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 53.46% |
| 10 | Jade Biosciences | 1.19 Bn | 873.71 Mn | - | -404.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -404.99% |
| Dec 31, 2025 | -53.54% |
| Sep 30, 2025 | -294.19% |
| Mar 31, 2025 | 54.02% |
| Dec 31, 2024 | 1,049.65% |
| Sep 30, 2024 | 406.29% |
| Mar 31, 2024 | -444.25% |
| Dec 31, 2023 | -39,395.45% |
| Sep 30, 2023 | -470.09% |
| Jun 30, 2023 | 5,133.72% |
| Mar 31, 2023 | 116.02% |
| Dec 31, 2022 | 99.98% |
| Sep 30, 2022 | -104.14% |
| Jun 30, 2022 | -101.35% |
| Mar 31, 2022 | -740.61% |
| Dec 31, 2021 | -4,292.55% |
| Sep 30, 2021 | 5,103.21% |